Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.
Hong, Y., Feng, Y., Sun, H., Zhang, B., Wu, H., Zhu, Q., Li, Y., Zhang, T., Zhang, Y., Cui, X., Li, Z., Song, X., Li, K., Liu, M., Liu, Y.(2021) FEBS Open Bio 11: 782-792
- PubMed: 33527708 
- DOI: 10.1002/2211-5463.13102
- Primary Citation of Related Structures:  
7CGW - PubMed Abstract: 
Programmed cell death protein 1 (PD-1), an immune checkpoint receptor expressed by activated T, B, and NK cells, is a well-known target for cancer immunotherapy. Tislelizumab (BGB-A317) is an anti-PD-1 antibody that has recently been approved for treatment of Hodgkin's lymphoma and urothelial carcinoma ...